Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo Bio CoTSE:3386 -0.08%73 EV-to-EBITDA is 4.97 as of Aug. 27, 2026, which is 32% below its 10-year median of 7.34. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,310.66 (Fairly Valued). The stock has 4 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 88.14% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cosmo Bio Co's enterprise value is 円3,631 Mil.
Cosmo Bio Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was 円730 Mil. Therefore, Cosmo Bio Co's EV-to-EBITDA for today is 4.97.
The historical rank and industry rank for Cosmo Bio Co's EV-to-EBITDA or its related term are showing as below:
TSE:3386'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.11 Med: 7.34 Max: 17.41
Current: 4.97
During the past 13 years, the highest EV-to-EBITDA of Cosmo Bio Co was 17.41. The lowest was 2.11. And the median was 7.34.
TSE:3386's EV-to-EBITDA is ranked better than 88.14% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.44
vs TSE:3386: 4.97
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cosmo Bio Co's PE Ratio (TTM) for today is calculated as:
Cosmo Bio Co's share price for today is 円1244.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was 円64.020.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cosmo Bio Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3386 vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Cosmo Bio Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's EV-to-EBITDA falls into.
Cosmo Bio Co's current Enterprise Value is 円3,631 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was 円730 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a EV-to-EBITDA of 4.97 as of Aug. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cosmo Bio Co. This is 32% below median its historical median of 7.34. Over the past decade, Cosmo Bio Co's EV-to-EBITDA has ranged from 2.11 to 17.41. According to the industry distribution chart, Cosmo Bio Co ranks #14 out of 118 companies in the Medical Diagnostics & Research industry, placing it in the top 11.9%.
Is Cosmo Bio Co's EV-to-EBITDA too high?
Cosmo Bio Co's current EV-to-EBITDA of 4.97 is 32% below median its 10-year median of 7.34. Over the past 10 years, this metric has ranged from a low of 2.11 to a high of 17.41. The Medical Diagnostics & Research industry median EV-to-EBITDA is 16.44. Cosmo Bio Co's value of 4.97 is 69.8% below this industry median. Based on the distribution chart, Cosmo Bio Co ranks #14 out of 118 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #14 out of 118 companies for EV-to-EBITDA. This places Cosmo Bio Co in the top 12% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 16.44. Cosmo Bio Co's value of 4.97 is 69.8% below this benchmark. Historically, Cosmo Bio Co's own EV-to-EBITDA has ranged from 2.11 to 17.41 over the past decade. While the company's 10-year median is 7.34 vs. the industry median of 16.44, Cosmo Bio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.44, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo Bio Co's current EV-to-EBITDA of 4.97 is 69.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cosmo Bio Co. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo Bio Co's current EV-to-EBITDA is 4.97, which is 32% below median its own 10-year median of 7.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,310.66, compared to a current price of 円1,244.00 — trading 5.1% below its estimated fair value. The current EV-to-EBITDA is 4.97, which is 32% below median its 10-year median of 7.34 and 69.8% below the Medical Diagnostics & Research industry median of 16.44. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current EV-to-EBITDA is 4.97 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be undervalued.
The current stock price of 円1,244.00 is trading 5.1% below its estimated GF Value™ of 円1,310.66.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
EV-to-EBITDA: 4.97 (32% below median its 10-year median of 7.34)
GF Value™: 円1,310.66 vs. price of 円1,244.00 (5.1% below fair value)
Industry Position: 69.8% below the Medical Diagnostics & Research median (#14 of 118)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
